Announced details
Induction therapy for moderate to severe active Crohn’s disease (limited to cases in which existing treatment has been inadequately effective)
The disclosure states that future business performance and other factors may fluctuate for various reasons. No specific impact amount has been disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Ustekinumab BS IV Infusion 130 mg “F”, Ustekinumab BS Subcutaneous Injection 45 mg Syringe “F”, Ustekinumab BS subcutaneous injection 90 mg syringe “F” |
| Launch date | Targeting NHI drug price listing and a launch in November 2026 (planned) |
| Applicable area | Induction therapy for moderate to severe active Crohn’s disease (limited to cases in which existing treatment has been inadequately effective) |
| Impact on Business Performance | The disclosure states that future business performance and other factors may fluctuate for various reasons. No specific impact amount has been disclosed. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the ustekinumab biosimilar product lineup and establish a structure capable of providing treatment options ranging from induction therapy to maintenance therapy for Crohn’s disease. The company also aims to contribute to the wider adoption of biosimilars in the inflammatory bowel disease field and improve patient access to treatment.